Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 17, 2024Hypertension ResearchOpen Access

A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension

View Full Paper
Ask AI
Bookmark
Share

Authors

FWFang WangShijiazhuang UniversityLLLing LiuShanghai Medical College of Fudan UniversityHRHongyun RuanXuzhou Central Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e6ebd1b6db6435876668b0https://doi.org/10.1038/s41440-024-01657-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Efficacy of Aliskiren Monotherapy and Ramipril Monotherapy in Patients with Stage 2 Systolic Hypertension: Subgroup Analysis of a Double‐blind, Active Comparator Trial2010 · 10 citations
  2. 2Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor2022 · 11 citations
  3. 3Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials2013 · 39 citations
  4. 4Direct Renin Inhibition: Focus on Aliskiren2007 · 55 citations
  5. 5Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension2010 · 54 citations